Source link : https://www.newshealth.biz/health-news/sustained-disease-control-in-adolescent-myasthenia-gravis-with-fcrn-blocker/
SAVANNAH, Ga. — Investigational nipocalimab plus standard of care achieved sustained reductions in immunoglobulin G (IgG) and appeared to be safe for adolescent patients with generalized myasthenia gravis (gMG), the phase II/III Vibrance-MG study showed. From baseline to week 24 of the active treatment phase, the mean percentage change in total serum IgG from baseline […]
Author : News Health
Publish date : 2024-10-19 22:54:31
Copyright for syndicated content belongs to the linked Source.